Business
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs\nLucid Diagnostics Investor Day, where Lucid executives, key opinion leaders, and other experts will discuss Lucid's business and technologies, to be held in New York City on December 13th\nNEW YORK, Nov. 9, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\"PAVmed\"), today announced that its CAP-accredited, CLIA-certified laboratory, LucidDx Labs, Inc., has launched the next generation of the EsoGuard® Esophageal DNA test (\"EsoGuard 2.0\") for the detection of esophageal precancer, having demonstrated enhanced assay performance and lower costs in extensive validation studies. All commercial and research samples received by the laboratory will now be processed using the EsoGuard 2.0 assay. Lucid also announced that it will be hosting an Investor Day on December 13, 2023, in New York City.\n\n \n \n \n \n \n \n\n \n\"The launch of EsoGuard 2.0 is a seminal milestone for our company and the culmination of over a year of meticulous R&D work by our Chief Scientific Officer, Suman Verma, M.D, Ph.D., and her dedicated and talented team,\" said Lishan Aklog, M.D., Lucid's Chairman & Chief Executive Officer. \"EsoGuard had previously demonstrated unprecedented cancer and precancer detection results, including detecting 100 percent of esophageal cancers and over 80 percent of precancers in a recent study from the National Cancer Institute-funded BETRNet consortium. EsoGuard 2.0 improves upon EsoGuard 1.0's already outstanding performance in multiple respects, including by enhancing DNA yield, streamlining down-stream processes that incorporate advanced molecular techniques and more efficient bioinformatics, and enabling higher-throughput testing. These improvements also lower the per-sample costs of the assay, which we expect to decrease even further in the coming months when we upgrade our NGS-sequencing platform to a higher-throughput model to accommodate increased EsoGuard testing volume. We appreciate the critical input of Sandy Markowitz, M.D., Ph.D., and his colleagues at Case Western Reserve Univ...